Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enoblituzumab with Retifanlimab or Tebotelimab in HNSCC
NCT04634825Phase 2Terminated
- Sponsor
- MacroGenics
- Start
- Mar 2021
- Primary completion
- Jul 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of enoblituzumab in head and neck squamous cell carcinoma (HNSCC), sponsored by MacroGenics. Started Mar 2021; status: terminated.
02
Drugs
enoblituzumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04634825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04634825.